Navigation Links
Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
Date:11/17/2010

protective therapies for the treatment of cardiovascular diseases - today announces positive six-month results, including significant functional and clinical benefit, from the Phase II clinical trial of its development programme C-Cure(R), designed as a novel stem cell therapy for heart failure based on breakthrough technology.

Forty-five patients with severe heart failure of ischemic origin participated in the C-Cure multicenter Clinical Trial in Belgium, Serbia and Switzerland, and were randomized to optimal standard of care (control group; n=24) or optimal standard of care plus C-Cure treatment (treatment group; n=21). The primary objective of this trial was to assess the safety and feasibility of C-Cure, a stem cell product candidate derived from the patient's own bone marrow and guided to cardiac lineage cells.

Beyond meeting the safety objective as assessed by an independent safety board, the trial revealed that six months after receiving C-Cure, patients in the treatment group showed significant improvements in a number of measures of their heart function.

Patients receiving the trial drug C-Cure saw an 18.1% increase in left ventricular ejection fraction (LVEF) over baseline at the six month follow-up point, as measured by echocardiography, while the mean LVEF increased only by 3.6% in patients enrolled in the control group. This difference in LVEF between the C-Cure treated and control patients was highly significant (p<0.0001).

The trial also generated data that suggest favorable remodelling of heart muscle and improved heart muscle performance in the treatment versus control group. Signs of functional improvement were supported by improved fitness, shown by a significant mean difference in the 6-minute walking distance test between the treatment and control groups.

In terms of feasibility, the bone marrow of 70% of the attempted 30 patients was successfully processed into C-Cure. The company is targeting even fur
'/>"/>

SOURCE Cardio3 BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Award Winning Mayo Clinic Scientist Joins Cardio3 BioSciences
2. Cardio3 BioSciences Announces Promising Pre-Clinical Data for Proprietary C-Cath(R) Catheter
3. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
4. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
5. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
6. Magellan Biosciences to Debut Revolutionary New Dynex® Clinical Diagnostics Processing System for Fully Automated ELISA Testing at MEDICA 2010
7. Sangamo BioSciences Announces Presentation at Lazard Capital Markets Healthcare Conference
8. Ambit Biosciences Strengthens Board of Directors and Executive Team
9. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
10. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
11. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... BURLINGTON, Mass. , Aug. 21, 2014 /PRNewswire/ ... of COPD,  physicians in Brazil ... to follow clinical guidelines and commonly prescribe long-acting ... regimens, although they do so within current severe ... combinations (FDCs) that are expected to launch in ...
(Date:8/21/2014)... , N.Y. and HAMBURG, Germany , Aug. ... it is collaborating with Deutsches Elektronen-Synchrotron ( DESY ), ... , to speed up management and storage of ... Data and Analytics architecture based on IBM software ... second of data at peak performance and help scientists ...
(Date:8/21/2014)... percent of Americans believe the abuse of strong prescription pain ... safety issue in the United States , ... & Partners, a Cincinnati based research ... the prescription medication abuse problem and the need for medical ... facing our country," Rex Repass , CEO of the ...
Breaking Medicine Technology:Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3
... ASHBURN, Va., Dec. 18 Innocoll, Inc., ... first of three planned,phase 2 clinical trials ... Ltd, to investigate CollaRx(R) GENTAMICIN TOPICAL for ... ulcers, has commenced,dosing., CollaRx GENTAMICIN TOPICAL ...
... RICHMOND, Va., Dec. 18 Insmed Inc. (Nasdaq:,INSM), ... that the Food and Drug Administration (FDA) has ... of Myotonic Muscular,Dystrophy (MMD). Insmed is currently conducting ... MMD, and recently was awarded a grant of,approximately ...
Cached Medicine Technology:Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers 4Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy 2Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy 3
(Date:8/21/2014)... Researchers have pinpointed the environmental source of fungal infections ... for decades. It literally grows on trees. , The ... 13-year-old girl, who spent the summer gathering soil and ... by infections of the fungus named Cryptococcus gattii ... which encompasses a number of species including C. ...
(Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Black mothers are ... and here,s one possible reason why: Hospitals in neighborhoods ... than those in areas with more white residents, a ... breast-feeding are much less common in medical centers where ... the U.S. Centers for Disease Control and Prevention reported ...
(Date:8/21/2014)... seniors, dimming vision may be tied to poorer survival, new ... aged 65 to 84, who were assessed when they enrolled ... later. Vision loss over time was associated with an ... period, the researchers reported. Although the study couldn,t prove ... University in West Lafayette, Ind., offered up some theories on ...
(Date:8/21/2014)... New York (PRWEB) August 21, 2014 ... against C.R. Bard, Inc. continue to move forward ... District Court, Southern District of West Virginia, Bernstein ... issued on August 14th, the Court has established ... that requires special handling, division, storage and preservation. ...
(Date:8/21/2014)... woman is to focus on her body in terms ... viewing her as a complete human being with thoughts ... problem in the media, how does it affect individual ... Women Quarterly , a SAGE journal, finds that more ... higher incidents of sexual pressure and coercion., Researchers Laura ...
Breaking Medicine News(10 mins):Health News:Fungus deadly to AIDS patients found to grow on trees 2Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 3Health News:Objectification in romantic relationships related to sexual pressure and coercion 2
... oldest and largest,consumer organization dedicated to preventing vaccine ... announced today that it,will launch a national public ... informed, voluntary decisions about vaccination in America., ... of vaccines recommended by,federal officials for children during ...
... twice as likely to suffer major trauma; more education, ... -- Knee injuries are the most common reason for ... on nine high school sports at 100 U.S. high ... basketball, baseball and wrestling, and girls, soccer, volleyball, basketball ...
... Medicare premiums have doubled since 2000, AUSTIN, ... AARP members and volunteers today delivered more than,20,000 ... Hutchison and John,Cornyn in Dallas and Austin, saying ... increases., (Logo: http://www.newscom.com/cgi-bin/prnh/20030514/AARPLOGO ), ...
... Outreach, LAKE SUCCESS, N.Y., May 29 IPRO, ... the quality,of health care, announced today that it has ... on Google will link users,with IPRO,s consumer-directed sites., ... help us,enormously in our efforts to make health care ...
... Condensing the sum of oncology know-how presented at ... Conference presents a great opportunity to benefit from ... in oncology presented by renowned professionals in the ... continuing medical education, professional development and clinical experience ...
... The Little Clinic, CINCINNATI and NASHVILLE, Tenn., May ... The Little Clinic LLC today announced a,partnership aimed at ... across the country. Kroger has made a significant,investment in ... Financial terms of the investment were not disclosed. The ...
Cached Medicine News:Health News:NVIC Launches 'Stand Up Be Counted Campaign' to Protect Voluntary Vaccination Decisions in America 2Health News:NVIC Launches 'Stand Up Be Counted Campaign' to Protect Voluntary Vaccination Decisions in America 3Health News:Knee Injuries Main Cause of HS Sports Surgeries 2Health News:AARP Protests Medicare Premium Increases, Delivering Over 20,000 Petitions to Senators Hutchison and Cornyn 2Health News:AARP Protests Medicare Premium Increases, Delivering Over 20,000 Petitions to Senators Hutchison and Cornyn 3Health News:IPRO Receives Google Advertising Grant 2Health News:ESMO Conference Lugano 2Health News:Kroger and The Little Clinic Establish Partnership to Offer Customers Convenient Healthcare Centers Inside Their Neighborhood Store 2Health News:Kroger and The Little Clinic Establish Partnership to Offer Customers Convenient Healthcare Centers Inside Their Neighborhood Store 3
... The Carriazo-Pendular microkeratome is based on ... the cornea during the cut., ,This ... evenly from the beginning of the ... that the intraocular pressure does not ...
... somatomedin-C, is a peptide highly dependent on ... activity. IGF-I is transported in serum by ... growth disorders, measurements of IGF-I are a ... secretion. A normal plasma or serum IGF-I ...
... The IDS OCTEIATM IGF-I kit is a ... Insulin-like Growth Factor-I (IGF-I) in serum or ... polyclonal "capture" antibody in microtiter wells and ... horseradish peroxidase. A simple sample pre-treatment replaces ...
Inquire...
Medicine Products: